Tempest Therapeutics, Inc.
TPST
$6.87
$0.385.86%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 6.08% | -20.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 31.91% | 10.11% | |||
| Operating Income | -31.91% | -10.11% | |||
| Income Before Tax | -30.85% | -10.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -30.85% | -10.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.85% | -10.30% | |||
| EBIT | -31.91% | -10.11% | |||
| EBITDA | -32.67% | -10.89% | |||
| EPS Basic | 17.63% | 3.65% | |||
| Normalized Basic EPS | 17.61% | 3.66% | |||
| EPS Diluted | 17.63% | 3.65% | |||
| Normalized Diluted EPS | 17.61% | 3.66% | |||
| Average Basic Shares Outstanding | 58.85% | 14.46% | |||
| Average Diluted Shares Outstanding | 58.85% | 14.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||